Significant Ownership of Caligan Partners LP

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for Caligan Partners LP focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
/s/ David Johnson - David Johnson, Managing Partner
Manager location
New York, NY

Follow Filing Activity

Follow Caligan Partners LP with Pro and return when a new Schedule 13D/G filing changes the record on this page.

Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.

Review Pro alert access Already have an account? Sign in and return here

Significant Ownership of Caligan Partners LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VRCA Verrica Pharmaceuticals Inc. Common Stock, par value $0.0001 per share 10% $43,635,492 6,503,054 0% Caligan Partners LP 26 Dec 2025
VRCA Verrica Pharmaceuticals Inc. Common stock, $0.0001 par value per share 10% $7,769,760 15,856,653 Caligan Partners LP 31 Dec 2024
ANIK Anika Therapeutics, Inc. Common Stock, par value $0.01 per share 10% $13,791,743 1,435,130 0% Caligan Partners LP 23 Jan 2026
SABS SAB Biotherapeutics, Inc. Common Stock, $0.0001 par value per share 8.8% $31,550,140 7,967,207 0% Caligan Partners LP 30 Jun 2026
IRD Opus Genetics, Inc. Common Stock, $0.0001 par value per share 7.3% $24,916,044 +$8,430 6,077,084 +0.03% Caligan Partners LP 30 Jun 2026
AVTX Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share 5.9% $60,777,866 +$29,369,074 3,163,866 +94% Caligan Partners LP 30 Jun 2026
CLRB Cellectar Biosciences, Inc. Common Stock, $0.00001 par value per share 5.9% $1,236,095 469,998 Caligan Partners LP 30 Jun 2026
LBRX LB PHARMACEUTICALS INC Common Stock, $0.0001 par value per share 5% $35,002,624 1,438,070 Caligan Partners LP 31 Mar 2026
FTH Faeth Therapeutics, Inc. Common Stock, par value $0.0001 per share 2.4% $22,761,527 +$18,205,294 629,467 +400% Caligan Partners LP 30 Jun 2026
EOLS Evolus, Inc. Common Stock, par value $0.00001 per share 0% $0 -$23,385,028 0 -100% Caligan Partners LP 31 Dec 2025
YMAB Y-mAbs Therapeutics, Inc. Common stock, par value $0.0001 per share 0% $0 -$20,169,863 0 -100% Caligan Partners LP 30 Sep 2025

Schedules 13D/G Reported by Caligan Partners LP:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .